Powerful prescription relief for ocular itch from allergic conjunctivitis This article is sponsored by Eyevance Pharmaceuticals, developing innovative and impactful ophthalmic therapies for the ocular surface and anterior segment. Allergic conjunctivitis (AC) is a common ocular condition. Worldwide, 15% to 20% of the population is affected by some form of allergic disease with ocular symptoms present in about 40% to 60% percent of those patients. More than a mere nuisance for many, ocular allergies have been shown to have an adverse impact on quality of life (QOL). In a cross-sectional study of 220 patients with ocular allergy, 25% had more than five episodes in the previous year and nearly 60% had episodes all year round. There was a significant impairment on overall QOL during an allergic conjunctivitis episode, with 46% rating their disease greater than 6 on a 10-point severity scale. Only 5.1% said their allergic conjunctivitis was mild or not severe. A total of 16% missed work or school due to their ocular allergy episode. Most patients (86%) reported allergic eye symptoms during the previous year, including itching (94.2%), tearing (84.3%), photophobia (67.4%), and half of them also reported ocular pain (51.1%).